HC Wainwright Issues Pessimistic Outlook for Harrow Earnings

Harrow, Inc. (NASDAQ:HROW) – Stock analysts at HC Wainwright reduced their Q3 2026 earnings estimates for Harrow in a research report issued on Wednesday, March 4th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of $0.20 per share for the quarter, down from their prior estimate of $0.29. HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Harrow’s Q4 2026 earnings at $0.40 EPS.

Several other brokerages have also recently commented on HROW. Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a report on Thursday, January 22nd. Zacks Research downgraded shares of Harrow from a “hold” rating to a “strong sell” rating in a research report on Tuesday. LADENBURG THALM/SH SH raised their price objective on shares of Harrow from $64.00 to $66.00 and gave the company a “buy” rating in a research report on Wednesday, November 12th. Cantor Fitzgerald dropped their target price on shares of Harrow from $94.00 to $91.00 and set an “overweight” rating for the company in a research note on Wednesday. Finally, William Blair restated an “outperform” rating on shares of Harrow in a research report on Tuesday. Eight equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $71.14.

Harrow Stock Down 7.8%

HROW stock opened at $36.17 on Thursday. The business’s 50-day simple moving average is $47.92 and its 200 day simple moving average is $43.71. Harrow has a twelve month low of $20.85 and a twelve month high of $54.85. The company has a market cap of $1.35 billion, a PE ratio of -212.75 and a beta of 0.05. The company has a quick ratio of 2.52, a current ratio of 2.20 and a debt-to-equity ratio of 4.67.

Harrow (NASDAQ:HROW) last issued its quarterly earnings data on Monday, March 2nd. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.23). Harrow had a positive return on equity of 36.51% and a negative net margin of 1.89%.The business had revenue of $89.09 million during the quarter, compared to the consensus estimate of $88.42 million.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Harrow during the 4th quarter worth about $26,000. Raymond James Financial Inc. acquired a new stake in shares of Harrow during the 2nd quarter worth approximately $48,000. SBI Securities Co. Ltd. increased its stake in Harrow by 393.5% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock valued at $52,000 after acquiring an additional 846 shares during the last quarter. State of Alaska Department of Revenue bought a new position in Harrow in the third quarter valued at approximately $83,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Harrow by 25.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock valued at $88,000 after purchasing an additional 369 shares in the last quarter. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow News Summary

Here are the key news stories impacting Harrow this week:

• Positive Sentiment: HC Wainwright kept a Buy rating and raised its price target to $70, signaling continued upside from that shop despite recent volatility. H.C. Wainwright PT Raised
• Positive Sentiment: Company reported record 2025 results and set a 2026 outlook, underscoring underlying revenue momentum that management says supports growth investments. Record 2025 Results
• Positive Sentiment: Management outlined a $350M–$365M 2026 revenue goal tied to salesforce expansion and pipeline progress — a constructive guide for top-line growth if execution holds. 2026 Revenue Goal
• Neutral Sentiment: Cantor Fitzgerald trimmed its price target slightly (from $94 to $91) but remains Overweight, leaving a large implied upside from current levels — mixed signal on conviction. Cantor Fitzgerald PT Change
• Neutral Sentiment: Management will present at the Leerink Global Healthcare Conference (Mar 10), giving investors another opportunity for management commentary and Q&A. Leerink Presentation
• Negative Sentiment: Zacks Research downgraded Harrow from Hold to Strong Sell, increasing bearish analyst pressure and likely contributing to near-term selling. Zacks Downgrade Coverage
• Negative Sentiment: HC Wainwright cut its Q3 and Q4 2026 EPS forecasts (Q3: $0.29 → $0.20; Q4: $0.51 → $0.40), reflecting weaker near-term profit expectations even while the firm keeps a Buy rating. HC Wainwright Estimate Cuts
• Negative Sentiment: Investors reacted to a disappointing Q4 EPS print (reported EPS well below consensus), margin pressure, and warnings about higher S&M and interest expense; analysts and outlets highlighted valuation and leverage concerns. Coverage and analyses explain the post-earnings selloff. Earnings Transcript SA Analysis Shares Gap Down

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.